Tyme reports Phase I data for TYME-88 in pancreatic cancer

Tyme Technologies Inc. (OTCQB:TYMI) reported data from 11 evaluable patients with refractory pancreatic cancer in an open-label, U.S. Phase I trial showing that TYME-88 (SM-88, SM88) led to 1 complete response, 2 partial responses and 8 cases of stable disease. Data were presented at the American Society of Clinical Oncology meeting in Chicago...